Pfizer concludes phase 3 study of COVID-19 vaccine candidate, says it's 95% effective
New York: Global drugmakers Pfizer and BioNTech said on Wednesday their COVID-19 vaccine candidate is 95 percent effective, including in people over 65 years of age, a major announcement coming just two days after Moderna said its virus vaccine has an efficacy rate of 94.5 percent.
Pfizer and BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints. Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.
This week, leading biotechnology company Moderna said its COVID-19 vaccine had shown to be 94.5 percent effective. Earlier this month, Pfizer and Biontech had said their COVID-19 vaccine candidate was found to be more than 90 percent effective in preventing COVID-19 in participants.
Analysis of the data indicates a vaccine efficacy rate of 95 percent in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from seven days after the second dose.
The company said the first primary objective analysis is based on 170 cases of COVID-19, of which 162 cases of coronavirus were observed in the placebo group while 8 cases in the BNT162b2 group.
Vaccine efficacy was consistent across age, gender, race, and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94 percent.
There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.
"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world," said Dr. Albert Bourla, Pfizer Chairman and CEO.
"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," Bourla said.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
SWR announces special trains for passengers stranded by large-scale IndiGo cancellations
Bengaluru (PTI): The South Western Railway on Saturday announced a series of special trains, in coordination with Central, South Eastern and Southern Railways, to clear stranded passengers following large-scale IndiGo flight cancellations across the country.
The special services will operate between December 6 and 10 on high-demand routes, including Bengaluru–Chennai, Bengaluru–Pune, Yesvantpur–Hazrat Nizamuddin, Shalimar–Yelahanka and Ernakulam–Yelahanka, officials said.
According to an official statement, SWR will run Train No. 06255/06256 between Chennai Egmore and KSR Bengaluru, 06257/06258 between Bengaluru and MGR Chennai Central, 06259/06260 between Yesvantpur and Hazrat Nizamuddin, and 06263/06264 between Bengaluru and Pune.
ALSO READ: Indigo flights chaos: SCR to run special trains to clear passenger rush
Central Railway will operate Train No. 01413/01414 between Pune and Bengaluru, while South Eastern Railway will run Train No. 08073/08074 between Shalimar and Yelahanka. Southern Railway will operate Train No. 06147/06148 between Ernakulam and Yelahanka, the statement said.
Railways has advised passengers to check updated timings on its official channels and arrive early at stations.
For at least five days in a row, IndiGo flight operations have been significantly disrupted, with a large number of cancellations and delays causing hardships to thousands of passengers. In many cases, baggage has been misplaced.
